Pyrazine

Pyrazine

SCHEMBL940753

[SnH4].c1cnccn1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31437084 0.93 TSHR (0.50)
Pyrazine SCHEMBL1226089 0.93 TSHR (0.50)
Pyrazine SCHEMBL5179 0.93
Pyrazine SCHEMBL8535297 0.86
Pyrazine SCHEMBL11336378 0.86
Pyrazine SCHEMBL6268122 0.86
Pyrazine SCHEMBL2682548 0.86
Pyrazine SCHEMBL21647787 0.86
Pyrazine SCHEMBL21176400 0.86
Pyrazine SCHEMBL10496031 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10098896-B2 C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity UNIVERSITY OF MARYLAND BALTIMORE (US) 2018-10-16 US disclosed
US-20180036320-A1 NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-02-08 US disclosed
CN-103608346-B As the 7-naphthyridine derivatives of hypoxia inducible factor (HIF) hydroxylase inhibitors 菲布罗根有限公司 2016-06-15 CN disclosed
US-9295679-B2 Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity UNIVERSITY OF MARYLAND, BALTIMORE (US) 2016-03-29 US disclosed
US-20150174143-A1 NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY UNIVERSITY OF MARYLAND, BALTIMORE 2015-06-25 US disclosed
US-9018198-B2 Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity UNIVERSITY OF MARYLAND (US) 2015-04-28 US disclosed
EP-2206719-B1 PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-17-(1-H-BENZIMIDAZOLE-1-YL)ANDROSTA-5,16-DIENE UNIV MARYLAND (US) 2014-10-22 EP disclosed
US-20140288036-A1 NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY THE UNIVERSITY OF MARYLAND, BALTIMORE (US) 2014-09-25 US disclosed
US-20140274983-A1 NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2014-09-18 US disclosed
CN-103608346-A Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase FIBROGEN INC 2014-02-26 CN disclosed
US-20100048524-A1 Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity UNIVERSITY OF MARYLAND, BALTIMORE 2010-02-25 US disclosed
US-20100048912-A1 Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity UNIVERSITY OF MARYLAND, BALTIMORE 2010-02-25 US disclosed
US-20100048914-A1 Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity UNIVERSITY OF MARYLAND, BALTIMORE 2010-02-25 US disclosed
US-20100048913-A1 Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity UNIVERSITY OF MARYLAND, BALTIMORE 2010-02-25 US disclosed
WO-2009120565-A2 NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2009-10-01 WO disclosed
EP-1853619-A4 NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY UNIV MARYLAND (US) 2009-08-26 EP disclosed
US-20080280864-A1 Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity UNIVERSITY OF MARYLAND, BALTIMORE 2008-11-13 US disclosed
CN-101107000-A 3,6-bicyclolides ENANTA PHARM INC (US) 2008-01-16 CN disclosed
EP-1853619-A1 NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY University of Maryland (US) 2007-11-14 EP disclosed
WO-2006093993-A1 NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY UNIVERSITY OF MARYLAND (US) 2006-09-08 WO disclosed